Incyte Genomics, Inc. (INCY) Reports Q4 EPS Loss of $0.44, Sales Top Expectations
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $120.89 +0.10%
Financial Fact:
Income (loss) from operations: 22.29M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Income (loss) from operations: 22.29M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Incyte Genomics, Inc. (NASDAQ: INCY) reported Q4 EPS of ($0.44), $0.05 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $28.9 million versus the consensus estimate of $25.65 million.
For earnings history and earnings-related data on Incyte Genomics, Inc. (INCY) click here.
For earnings history and earnings-related data on Incyte Genomics, Inc. (INCY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies sees a buying opportunity in this S&P 500 sector
- DA Davidson Reiterates Neutral Rating on Nebius Group (NBIS)
- Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
